Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Ryr7.8
Red Yeast Rice – Forschung
Hilft wahrscheinlich
51 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Red Yeast Rice scheint in 16 von 17 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2009–2026 mit einer typischen Studiengröße von 158 Teilnehmenden.
Basierend auf 51 Studien · 16 Meta-Analysen · 17 RCTs · 40,556 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
16geholfen1unklar· 34 weitere ohne bewertete Effektdaten
Nach Outcome
Cholesterol & lipidsReduziertes LDL-Cholesterin innerhalb von 4-8 Wochen · 4-8 weeks
Hilft wahrscheinlich45 Studien
Safety profile
Hilft wahrscheinlich18 Studien
Heart & blood pressureReduziertes LDL-Cholesterin innerhalb von 4-8 Wochen · 4-8 weeks
Hilft wahrscheinlich10 Studien
InflammationSignifikante Senkung des LDL-Cholesterins · 8-12 weeks
Überwiegend Mechanismus / Beobachtung3 Studien
Glucose & metabolicSenkt das LDL-Cholesterin über natürliches Monacolin K · 4-8 weeks
Zu wenige bewertete Studien2 Studien
Liver health
Zu wenige bewertete Studien2 Studien
In Zahlen
Aus 41 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
86%
über Studien hinweg
Untersuchte Personen
41k
typische Studie: 158 Personen
Stärkste Designs
33
16 gepoolt, 17 randomisiert
Zeigte Nutzen
94%
16/17 Studien
Wie lange Studien liefen
1–3 Monate
3
3+ Monate
3
Untersuchte Populationen
Patients with hyperlipidemia2
Patients with hypercholesterolemia2
Hypercholesterolemic patients2
Hyperlipidemia patients2
Aktives Forschungsgebiet
32 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
200920172026
1Total cholesterol reductionMeta-AnalyseCited 6×n=4,838 · very large study2024
Berberine, alone or with other nutraceuticals, can provide a modest positive impact on lipid concentrations.
Hernandez AV et al. · Journal of dietary supplements (2024)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Products with berberine alone had less robust effects on TC (MD -12.08 mg/dL [95%CI: -21.79 to -2.37]), LDL (MD -9.26 mg/dL [95%CI: -20.31 to 1.78]), and HDL (MD 1.38 mg/dL [95%CI: -1.27 to 4.03]) but TG effects were similar (MD -17.40 mg/dL [95%CI: -32.57 to -2.23]).
Berberine, alone or with other nutraceuticals, can provide a modest positive impact on lipid concentrations.
3Serum lipids, glucose, and hs-CRP improvementMeta-AnalyseCited 15×n=1,050 · large study2021
These changes are consistent with improved cardiometabolic health.
Cicero AFG et al. · Nutrients (2021)
Armolipid Plus® was well tolerated.
This meta-analysis demonstrates that dietary supplementation with Armolipid Plus® is associated with clinically meaningful improvements in serum lipids, glucose, and hs-CRP.
These changes are consistent with improved cardiometabolic health.
5Plasma lipid and glucose levelsMeta-AnalyseCited 80×n=1,670 · large study2016
Inverse variance-weighted mean differences (WMDs) and 95% confidence intervals (CIs) were calculated for net changes in lipid and glucose levels using a random-effects model.
Pirro M et al. · Pharmacological research (2016)
Spürbar Nutzen
← SchlechterKein EffektBesser →
Likely real
Inverse variance-weighted mean differences (WMDs) and 95% confidence intervals (CIs) were calculated for net changes in lipid and glucose levels using a random-effects model.
Overall, WMDs were significant for the impact of NComb supplementation on plasma levels of total cholesterol (-26.15mg/dL, p<0.001), LDL-cholesterol (-23.85mg/dL, p<0.001), HDL-cholesterol (2.53mg/dL, p<0.001), triglycerides (-13.83mg/dL, p<0.001) and glucose (-2.59mg/dL, p=0.010).
NComb-induced amelioration of lipid profile was not affected by duration of supplementation nor by baseline lipid levels; conversely, a greater glucose-lowering effect of NComb was found with higher baseline glucose levels and longer durations of supplementation.
6LDL cholesterol and total cholesterol levelsMeta-AnalyseCited 20×n=1,246 · large study2017
Although RYR appears to be a safe and effective lipid-lowering agent, there is insufficient evidence to support the recommendation of RYR supplementation to patients.
Peng D et al. · The American journal of nursing (2017)
Significant reductions in low-density lipoprotein cholesterol and total cholesterol levels with RYR supplementation were observed in all trials.
Although RYR appears to be a safe and effective lipid-lowering agent, there is insufficient evidence to support the recommendation of RYR supplementation to patients.
Further research is needed, including long-term studies, studies that include participants with comorbidities and complex medical histories, and studies that take into account the variability of formulation and dosage of RYR in the marketplace.
9Dyslipidemia managementMeta-AnalyseCited 84×n=804 · large study2014
The meta-analysis suggests that red yeast rice is an effective and relatively safe approach for dyslipidemia.
Li Y et al. · PloS one (2014)
The meta-analysis suggests that red yeast rice is an effective and relatively safe approach for dyslipidemia.
However, further long-term, rigorously designed randomized controlled trials are still warranted before red yeast rice could be recommended to patients with dyslipidemia, especially as an alternative to statins.
10Safety outcomesMeta-AnalyseCited 2×n=61 · small study2024
The evidence examined in this study suggests that RYR preparations are safe; however, the credibility of the evidence was not high.
Ma ZY et al. · Journal of integrative medicine (2024)
Based on A MeaSurement Tool to Assess Systematic Reviews version 2, 3 (20%) and 12 (80%) of these meta-analyses had low and critically low confidence, respectively.
The other 46 (75.4%) associations showed no significant difference between the use of RYR preparations and control treatments.
Regarding the credibility of the evidence, 21 (34.4%), 34 (55.7%) and 6 (9.8%) associations showed moderate, low and very low credibility, respectively.
11Total cholesterol and LDL-C reductionMeta-AnalyseCited 10×2024
Further research on specific subpopulations and outcomes could establish a consensus on determining the clinical benefits and potential risks, if any, of this nutraceutical.
Trogkanis E et al. · Nutrients (2024)
The consumption of RYR extract by people with hypercholesterolemia was associated with statistically significant reduction in total cholesterol and LDL-C, whereas it was not associated with an increase in life-threatening side effects.
As regards the safety, RYR extract was considered a safe choice with neither threatening nor frequent side effects.
Further research on specific subpopulations and outcomes could establish a consensus on determining the clinical benefits and potential risks, if any, of this nutraceutical.
13Cholesterol and triglyceride reductionMeta-AnalyseCited 13×2022
Xuezhikang was found to have the highest probability of being the most effective formulation for reducing total cholesterol and low-density lipoprotein cholesterol levels, while Zhibituo had the highest probability of being the most effective for controlling triglyceride and high-density lipoprotein cholesterol levels.
Xu G et al. · Endocrinology, diabetes & metabolism (2022)
In terms of reduced total cholesterol levels, Xuezhikang (SUCRA: 84.5%) had the highest probability of being the most effective formulation, with Simvastatin (66.4%) and Zhibitai (65.4%) ranked second and third, respectively.
Xuezhikang also had the highest probability of reducing low-density lipoprotein cholesterol levels to the greatest extent (SUCRA: 82.6%) with Simvastatin (SUCRA: 74.9%) and Zhibituo (SUCRA: 52.8%) being the second and third choices, respectively.
For reduced triglyceride levels, Zhibituo (SUCRA: 80.2%) exhibited the highest probability of being the most effective, with Xuezhikang (SUCRA: 63.4%) and Simvastatin (SUCRA: 57.6%) in second and third places, respectively.
Various MediterrAsian diet products or natural extracts may represent a potential intervention treatment to raise HDL-C in dyslipidemic subjects.
Rondanelli M et al. · BioMed research international (2016)
The results of this systematic review indicate that the dietary supplementation with red yeast rice, bergamot, artichoke, and virgin olive oil has promising effects on the increase of HDL-C serum levels.
Various MediterrAsian diet products or natural extracts may represent a potential intervention treatment to raise HDL-C in dyslipidemic subjects.
This meta-analysis confirms that the nutraceutical combination containing berberine, policosanol, and red yeast rice has shown to be an effective product for the improvement of the lipid profile.
Millán J et al. · Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis (2016)
Kaum spürbar Nutzen
← SchlechterKein EffektBesser →
The effect size (relative change from baseline (%)) was -1.3 (9.9%) for total cholesterol, -1.17 (-13.7%) for LDL-c, +0.17 (+3.7%) for HDL-c and -0.24 (-7.0%) for Triglycerides.
This meta-analysis confirms that the nutraceutical combination containing berberine, policosanol, and red yeast rice has shown to be an effective product for the improvement of the lipid profile.
This meta-analysis indicated that RYR extract in MI patients with borderline hypercholesterolemia is associated with improved cardiovascular outcomes and lipid profiles.
Sungthong B et al. · Scientific reports (2020)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
RYR extract (1,200 mg/day) reduced nonfatal MI (risk ratio (RR) = 0.42, 95% CI 0.34 to 0.52), revascularization (RR = 0.58, 95% CI 0.48 to 0.71), and sudden death (RR = 0.71, 95% CI 0.53 to 0.94).
Follow-up periods ranged from 4 weeks - 4.5 years and the studies were overall of high quality with low risk of bias.
This meta-analysis indicated that RYR extract in MI patients with borderline hypercholesterolemia is associated with improved cardiovascular outcomes and lipid profiles.
19LDL and total cholesterol reductionMeta-AnalyseCited 25×n=1,012 · large study2022
RYR at 200-4800 mg daily appears to be a safe and effective treatment for hyperlipidemia, effectively regulating blood lipid levels with an exceptional impact on TG.
Li P et al. · Frontiers in Pharmacology (2022)
Groß Nutzen
← SchlechterKein EffektBesser →
Compared with nutraceutical, RYR significantly reduced TC (MD, -17.80; 95% CI, -27.12 to -8.48; p = 0.0002) and LDL-C (MD, -14.40; 95% CI, -22.71 to -6.09; p = 0.0007).
In comparison to statins, RYR was more effective in lowering TG and comparable in lowering LDL-C and elevating HDL-C.
Whether alone or in combination, RYR did not increase the risk of adverse events in patients with hyperlipidemia.
A methodology for the calculation of the CLCI is presented, alongside potential applications in food labeling, clinical guidance, and dietary planning.
Jacobo-Velázquez DA. · Nutrients (2025)
Strategies for the design of next-generation cholesterol-lowering foods are discussed, such as combining multiple bioactives for synergistic effects, personalized nutrition approaches, and novel food processing techniques to enhance bioavailability.
Building on these strategies, the CLCI is then proposed as a practical scoring system, analogous to the glycemic index for blood sugar, that integrates the evidence-based potency of ingredients, effective dosing, and synergistic interactions into a single metric.
A methodology for the calculation of the CLCI is presented, alongside potential applications in food labeling, clinical guidance, and dietary planning.